BG Medicine Inc
OTC:BGMD
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
BG Medicine Inc
OTC:BGMD
|
11 USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
192B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.7B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280.9B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.7B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.2B HKD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
BG Medicine Inc
Glance View
BG Medicine, Inc. is a life sciences company. The company is headquartered in Foxboro, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
Over the last 3 years, BG Medicine Inc’s Gross Margin has increased from 66% to 67.8%. During this period, it reached a low of 65.5% on Mar 31, 2015 and a high of 68.3% on Jun 30, 2014.
